atai Life Sciences (ATAI), the largest pureplay clinical-stage psychedelic company in our index, just reported financial results for the fourth quarter and full-year ended December 31, 2021.
The announcement falls on the heels of Compass Pathways (CMPS), Field Trip Health (FTRP), and Mind Medicine (MNMD) all announcing their year-end results, marking a suitable time for investors to draw comparisons.
How did ATAI’s 2021 results match up with the others? And is their cash position sustainable for future growth?
Tune in to our latest video breakdown below discussing the results, investor reactions, technical price analysis, and more.